Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
41 hedge funds and large institutions have $30M invested in Merrimack Pharmaceuticals, Inc. in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 14 reducing their positions, and 4 closing their positions.
50% more call options, than puts
Call options by funds: $203K | Put options by funds: $135K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 43 → 41 (-2)
38% less capital invested
Capital invested by funds: $48.1M → $30M (-$18M)
43% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 14
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.54M |
| 2 |
Belvedere Trading
Chicago,
Illinois
|
+$92.6K |
| 3 |
NM
Newtyn Management
New York
|
+$42K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$18.2K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$13.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bronte Capital Management
Bondi Junction,
Australia
|
-$3.44M |
| 2 |
WSL
Western Standard LLC
Los Angeles,
California
|
-$448K |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$286K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$128K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$115K |
MACK Hedge Fund Activity: Q3 2022 in Review
41 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q3 2022, worth a combined $30M — down 38% from $48.1M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of MACK and 2 opened new positions — a net loss of 2 holders — while 14 trimmed existing stakes and 8 added.
The largest buyer was Point72 Asset Management, adding an estimated $3.54M. The largest seller was Bronte Capital Management, exiting entirely with an estimated $3.44M sold.
- 41 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q3 2022, down from 43 in Q2 2022.
- Funds reported $30M of Merrimack Pharmaceuticals, Inc. stock for Q3 2022, down 38% quarter-over-quarter.
- 2 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q3 2022 and 4 closed out, a net change of -2 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q3 2022 was Point72 Asset Management, an estimated $3.54M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q3 2022 was Bronte Capital Management, an estimated $3.44M sold.
Based on aggregated 13F filings for Q3 2022.